Search Results

AxoSim, Inc. announced completion of its acquisition of the microBrain™ associated assets of Vyant Bio’s StemoniX subsidiary.

AxoSim, Inc., a leader in the development and application of human biomimetic platforms for neurological diseases, and Vyant Bio, Inc. (OTC: VYNT) (Vyant Bio) today announced that they have entered into a definitive agreement under which AxoSim will acquire the microBrain™-associated assets of Vyant Bio’s StemoniX subsidiary.

Vyant Bio, Inc. announced that it has completed the sale of all or substantially all of the assets of the Company pursuant to an Asset Purchase Agreement dated July 13, 2023.

Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced the results of its March 24, 2021 shareholder meeting to approve the upcoming merger with StemoniX, Inc. (“StemoniX”).

.Maple Grove, Minnesota--(Newsfile Corp. - January 11, 2021) - StemoniX, a biotech company changing how new drugs are discovered, announced today their participation at the 2021 Biotech Showcase™ being held January 11-15th as part of OrganAi, a joint venture between StemoniX and Atomwise.

Cancer Genetics, Inc., an emerging leader in novel drug discovery techniques, and StemoniX, Inc., a company empowering the discovery of new medicines through the convergence of novel human biology and software technologies, announced their recently approved transaction has closed, and in connection with the merger, Cancer Genetics, Inc. was renamed Vyant Bio, Inc. effective March 30, 2021.

Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), and StemoniX, Inc., today announced the entry into a definitive merger agreement. Cancer Genetics is a leader in drug discovery and preclinical oncology and immuno-oncology services.

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, and StemoniX, Inc., a company empowering the discovery of new medicines through the convergence of novel human biology and software technologies, today announced a joint proof-of-concept program. StemoniX and vivo Pharm ® , a subsidiary of Cancer Genetics, recently launched a joint proof-of-concept p

StemoniX, Inc., a leader in human microOrgan® platforms for drug discovery and development, announced today that its Co-Founder and Chief Executive Officer Ping Yeh will present at Biotech Showcase 2020, to be held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco.

StemoniX, Inc. and Atomwise Inc. today announced a joint venture that combines StemoniX’s human microOrgan® platform with Atomwise’s AI technology to enable the rapid discovery and development of novel small molecule therapies.